Value through Innovation30 October 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

15.06.2014

Type 2 Diabetes: Physicians worldwide agree early conversations are crucial in the management of condition

- For Non-US and Non-UK Media
14.06.2014

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar in Safety and Efficacy to Lantus®

- For Non-U.S. and Non-UK Media
10.06.2014

Diabetes: Boehringer Ingelheim and Eli Lilly and Company Alliance to have 43 Presentations Featured at the American Diabetes Association’s 74th Scientific Sessions®

- For Non-US and Non-UK Media
06.06.2014

Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism

- For media outside of the U.S., the UK & Cananda only
05.06.2014

EMA accepts marketing authorisation application for nintedanib* in IPF

- For non-US health media only
03.06.2014

Boehringer Ingelheim Announces Successful Resolution of FDA Warning Letter

02.06.2014

New data show Giotrif® (afatinib) provided more than one year additional survival for lung cancer patients with the most common type of EGFR mutation (del19) compared to chemotherapy

- For Ex-US and Ex-UK Media Only
30.05.2014

ASCO 2014: Boehringer Ingelheim to present latest oncology research, including overall survival results for Giotrif® (afatinib) in advanced NSCLC

- For Ex-US and Ex-UK Media Only
28.05.2014

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate) litigation

23.05.2014

Type 2 Diabetes: European Commission approves Jardiance® (empagliflozin)

- For Non-U.S. and Non-U.K. Media
22.05.2014

Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients

- For media outside of the U.S., the UK & Canada only
21.05.2014

ATS 2014
COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva®) alone

- For media outside UK, U.S. and Canada
19.05.2014

Additional results from post-hoc analysis underline effectiveness of SPIRIVA®

- For ex-US and ex-UK Media Use Only  
18.05.2014

IPF Phase III results published in NEJM show nintedanib* slows disease progression

- For non-US health media only
15.05.2014

As the benefits and safety of Pradaxa® (dabigatran etexilate) are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa® to help more patients

- For media outside of the U.S., the UK & Canada only
15.05.2014

New analysis shows Boehringer Ingelheim’s Giotrif® (afatinib) is the first treatment to demonstrate significant overall survival benefit for patients with a specific type of lung cancer

- For Ex-US and Ex-UK Media Only
12.05.2014

Boehringer Ingelheim will make detailed clinical trial data available to the scientific community

07.05.2014

New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

- For media outside of the U.S., the UK & Canada only